Abbott Laboratories [ABT] stock is trading at $135.20, down -0.26%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ABT shares have gain 4.77% over the last week, with a monthly amount glided 4.09%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Abbott Laboratories [NYSE: ABT] stock has seen the most recent analyst activity on October 08, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $130. Previously, Piper Sandler started tracking the stock with Overweight rating on September 19, 2024, and set its price target to $131. On July 30, 2024, downgrade downgraded it’s rating to Hold. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $121 on May 30, 2024. Wolfe Research upgraded its rating to a Peer Perform. Morgan Stanley downgraded its rating to Equal-Weight for this stock on May 30, 2023, but kept the price target unchanged to $112. In a note dated April 20, 2023, Wolfe Research reiterated an Underperform rating on this stock and revised its target price from $107 to $103.
Abbott Laboratories [ABT] stock has fluctuated between $99.71 and $141.23 over the past year. Currently, Wall Street analysts expect the stock to reach $137.5 within the next 12 months. Abbott Laboratories [NYSE: ABT] shares were valued at $135.20 at the most recent close of the market. An investor can expect a potential return of 1.7% based on the average ABT price forecast.
Analyzing the ABT fundamentals
Abbott Laboratories [NYSE:ABT] reported sales of 42.34B for the trailing twelve months, which represents a growth of 3.95%. Gross Profit Margin for this corporation currently stands at 0.56% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.17%, and Net Profit Margin reading is 0.32%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.24 and Total Capital is 0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Abbott Laboratories’s Current Ratio is 1.78. Also, the Quick Ratio is 1.27, while the Cash Ratio stands at 0.5. Considering the valuation of this stock, the price to sales ratio is 5.56, the price to book ratio is 4.82 and price to earnings (TTM) ratio is 17.54.
Transactions by insiders
Recent insider trading involved Blount Sally E., Director, that happened on Apr 30 ’25 when 2600.0 shares were sold. Director, SALLY E BLOUNT completed a deal on Apr 30 ’25 to buy 2600.0 shares. Meanwhile, EVP AND GROUP PRESIDENT Earnhardt Lisa D sold 91167.0 shares on Mar 06 ’25.
